Novel N⁹-Substituted 6-Cycloalkylaminoadenines as Promising Compounds Against Triple Negative Breast Cancer

Area of Science:

• Medicinal Chemistry
• Cancer Biology
• Drug Discovery

Background:

• Triple negative breast cancer (TNBC) is an aggressive subtype with limited treatment options.
• Purine derivatives are recognized for their anticancer properties, warranting investigation for novel therapies.
• There is a critical need for innovative therapeutic strategies to combat TNBC.

Purpose of the Study:

• To synthesize and evaluate novel 6-cycloalkylaminoadenine compounds for anticancer activity.
• To elucidate the mechanism of action of these compounds in TNBC.
• To identify potential drug candidates for TNBC treatment.

Main Methods:

• Synthesis of two series of 6-cycloalkylaminoadenines via imidazole-based amidrazone precursors.
• Cytotoxicity assessment on the MDA-MB-231 TNBC cell line.
• Evaluation of effects on cell migration, invasion, actin cytoskeleton, and apoptosis markers (caspase-3, DNA fragmentation).
• Molecular docking studies against key cancer-related proteins, including CDK1.

Main Results:

• Novel 6-cycloalkylaminoadenines were successfully synthesized.
• Compounds exhibited cytotoxicity against TNBC cells with IC50 values in the 60-70 μM range.
• Compound 3.2a demonstrated significant inhibition of TNBC cell migration and invasion.
• Compound 3.2a induced apoptosis via caspase-3 activation and DNA fragmentation.
• Molecular docking indicated a high affinity of compound 3.2a for CDK1.

Conclusions:

• 6-Cycloalkylaminoadenines represent a promising class of compounds for TNBC therapy.
• Compound 3.2a exhibits multifaceted anticancer effects, including anti-migratory, anti-invasive, and pro-apoptotic activities.
• Further investigation into 6-cycloalkylaminoadenines, particularly compound 3.2a, is warranted for TNBC drug development.